Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Gains from Sales and Divestitures: 2013-2017

Historic Gains from Sales and Divestitures for Tenax Therapeutics (TENX) over the last 4 years, with Sep 2017 value amounting to $116,525.

  • Tenax Therapeutics' Gains from Sales and Divestitures rose 48452.08% to $116,525 in Q3 2017 from the same period last year, while for Sep 2017 it was $116,525, marking a year-over-year increase of 48452.08%. This contributed to the annual value of $16 for FY2016, which is N/A change from last year.
  • Latest data reveals that Tenax Therapeutics reported Gains from Sales and Divestitures of $116,525 as of Q3 2017, which was down 0.00% from $116,525 recorded in Q2 2017.
  • Tenax Therapeutics' 5-year Gains from Sales and Divestitures high stood at $116,525 for Q2 2017, and its period low was -$17,700 during Q3 2014.
  • In the last 3 years, Tenax Therapeutics' Gains from Sales and Divestitures had a median value of $240 in 2016 and averaged $37,282.
  • In the last 5 years, Tenax Therapeutics' Gains from Sales and Divestitures tumbled by 1,378.90% in 2014 and then surged by 151,163.64% in 2017.
  • Over the past 5 years, Tenax Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $50,062 in 2013, then tumbled by 40.48% to $29,796 in 2014, then surged by 100.49% to $174 in 2015, then crashed by 90.80% to $16 in 2016, then surged by 48,452.08% to $116,525 in 2017.
  • Its last three reported values are $116,525 in Q3 2017, $116,525 for Q2 2017, and $116,473 during Q1 2017.